Search

Meclinertant

AZD0947

As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline. … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.

Pivekimab sunirine

Volociximab

Naproxcinod

Tanaproget

Because of this tanaproget may prove to produce fewer side effects in comparison. It is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals. … An analog of tanaproget, 4-fluoropropyltanaproget (18F), has been developed as a radiotracer for imaging of the PR in positron emission tomography.

Linaprazan glurate

Linaprazan glurate is under investigation in clinical trial NCT07037875 (A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due … Linaprazan glurate is a small molecule drug. The usage of the INN stem '-prazan' in the name indicates that Linaprazan glurate is a proton pump inhibitor, not dependent on acid activation.

Valerian

Valerian has been used in the treatment of conditions including sleep disorders, anxiety, attention deficit-hyperactivity disorder (ADHD) and joint pain. … Valerian is extracted from a herb that is a perennial flowering plant. Valerian root is reported to have sedative and anxiolytic effects however its mechanism of action is not completely understood.

Olinciguat

, Olinciguat (IW-1701), in Healthy Volunteers). … Olinciguat is under investigation in clinical trial NCT03892499 (A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator

Interferon alfacon-1

Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. … Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon.